10.22376/ijpbs.2019.10.1.p1-12 Volume 4 Issue 2 2013 (April - June) Budesonide containing ethyl cellulose /eudragit RLPO compression coated tablets were prepared and there in vitro behavior tested for colonic delivery. Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineral corticoid activity. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic and non-allergic-mediated inflammation. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in ulcerative colitis, crohn's disease and inflammatory bowel disease. In this study, each 150 mg core tablet of budesonide was compression coated with 60% ethyl cellulose and 40% eudragit RLPO, 70% ethyl cellulose and 30% eudragit RLPO and 80% ethyl cellulose and 20% eudragit RLPO at a coat weight of 200 mg, 250 mg and 300 mg respectively. Drug release studies were carried out in pH 6.8 phosphate buffer IP solution. The Eudragit RLPO/Ethyl cellulose envelope was found to be a good delivery system for budesonide to be delivered to the colon. SHENDGE RAOSAHEB SOPAN AND SAYYAD FAHIM J Budesonide, CDDS, compression coated tablet. 45-57